Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q1

4886.TEDINET S100RJLW
Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥16.0bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.8bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥89.2bnat 2023-06-30Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥84.8bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥32.3bnat 2023-06-30Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥15.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥50.512023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.8%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥55m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥13m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥27m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥288m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥1m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥13m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 323
ItemContextValueUnit
Net salesPrior1YTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember13646000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember1593000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember44000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember15284000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-15000000JPY
Net salesPrior1YTDDuration15269000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember1728000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember124000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-18000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember1833000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-169000000JPY
Operating incomePrior1YTDDuration1664000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember14420000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember1560000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember42000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember16023000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration16023000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember13000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember13000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-13000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember14420000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember1560000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember55000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember16036000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-13000000JPY
Net salesCurrentYTDDuration16023000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E35791-000PharmaceuticalBusinessReportableSegmentsMember2021000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E35791-000AnimalHealthBusinessReportableSegmentsMember-1000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-27000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1993000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-288000000JPY
Operating incomeCurrentYTDDuration1704000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-07
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第３期第１四半期（自　2023年４月１日　至　2023年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)あすか製薬ホールディングス株式会社
Company name in english cover pageFilingDateInstantASKA Pharmaceutical Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　山口　隆
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝浦二丁目５番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)（03）5484－8845（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)グループ経理部長　　市川　学
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区芝浦二丁目５番１号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)（03）5484－8845（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)グループ経理部長　　市川　学

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass